Proton Pump Inhibitors in Cirrhotic Patients

Inappropriate Use of Proton Pump Inhibitors in Patients With Liver Cirrhosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06384443

Enrollment

1000

Registered

2024-04-25

Start date

2020-10-01

Completion date

2024-03-01

Last updated

2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Proton Pump Inhibitor Adverse Reaction

Keywords

Proton pump inhibitors, liver cirrhosis, spontaneous bacterial peritonitis, hepatic encephalopathy, portal hypertension

Brief summary

Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients. The patterns of use of PPIs will be classified into two groups based on adherence to the proven indications: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. We will estimate the prevalence of PPI misuse in cirrhotics and correlate it with different factors.

Detailed description

The inappropriate use of PPIs in cirrhosis patients is a growing concern. Evidence supporting the use of PPIs in cirrhosis-related conditions is limited. Several adverse outcomes have been linked to PPI use in cirrhosis, including an increased risk of spontaneous bacterial peritonitis and hepatic encephalopathy. The study aimed to assess the appropriateness of prescribing PPIs to patients with cirrhosis, examining its impact on prescribing practices and identifying associated factors. in this observational, descriptive, cross-sectional study, cirrhotic patients receiving proton pump inhibitors will be included in the study. Enrolled patients will classified according to the indication for PPI administration: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. Use of PPI will be considered inappropriate when prescribed without approved indication or used for a prolonged period beyond the recommended duration. The prevalence of PPI misuse in cirrhotics will be estimated and multivariate analyses will be conducted in order to identify independent predictors of inappropriate use of PPI.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

* Patients receiving proton pump inhibitors at the time of enrollment.

Exclusion criteria

* Refusal to sign the informed consent form or failure to provide the required information

Design outcomes

Primary

Measure	Time frame	Description
Inappropriate use of PPIs	Six weeks after study completion	Explore the prevalence of using PPIs without approved indication or for a prolonged period beyond the recommended duration in patients with liver cirrhosis
Predictors for inappropriate use of PPIs	Eight weeks after study completion	Determine independent predictors of inappropriate use of PPIs in patients with liver cirrhosis using multivariate analyses.

Countries

Egypt

Outcome results